Item 2.02. Results of Operations and Financial Condition.

On August 5, 2020, Lyra Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended June 30, 2020. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits



The following exhibit relating to Item 2.02 shall be deemed to be furnished, and
not filed:




               Exhibit
                 No.     Description

               99.1        Press Release issued on August 5, 2020

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses